Hypertensive nephropathy screening

Jump to navigation Jump to search

Hypertensive nephropathy Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Differentiating Hypertensive Nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Abdominal X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypertensive nephropathy screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypertensive nephropathy screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypertensive nephropathy screening

CDC on Hypertensive nephropathy screening

Hypertensive nephropathy screening in the news

Blogs on Hypertensive nephropathy screening

Directions to Hospitals Treating Hypertensive nephropathy

Risk calculators and risk factors for Hypertensive nephropathy screening

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]

Screening

  • Microalbuminuria (less than 300 mg/ dl) is the first sign of renal damage secondary to hypertension.
  • It is widely used as a screening technique to detect renal damage at an early stage.

References

Template:WH Template:WS